BACKGROUND: The RTS,S/AS malaria vaccine is being developed for delivery through the World Health Organization's Expanded Program on Immunization (EPI). We assessed the feasibility of integrating RTS,S/AS02D into a standard EPI schedule for infants. METHODS: In this phase 2B, single-center, double-blind, controlled trial involving 340 infants in Bagamoyo, Tanzania, we randomly assigned 340 infants to receive three doses of either the RTS,S/AS02D vaccine or the hepatitis B vaccine at 8, 12, and 16 weeks of age. All infants also received a vaccine containing diphtheria and tetanus toxoids, whole-cell pertussis vaccine, and conjugated Haemophilus influenzae type b vaccine (DTPw/Hib). The primary objectives were the occurrence of serious adverse events during a 9-month surveillance period and a demonstration of noninferiority of the responses to the EPI vaccines (DTPw/Hib and hepatitis B surface antigen) with coadministration of the RTS,S/AS02D vaccine, as compared with the hepatitis B vaccine. The detection of antibodies against Plasmodium falciparum circumsporozoite and efficacy against malaria infection were secondary objectives. RESULTS: At least one serious adverse event was reported in 31 of 170 infants who received the RTS,S/AS02D vaccine (18.2%; 95% confidence interval [CI], 12.7 to 24.9) and in 42 of 170 infants who received the hepatitis B vaccine (24.7%; 95% CI, 18.4 to 31.9). The results showed the noninferiority of the RTS,S/AS02D vaccine in terms of antibody responses to EPI antigens. One month after vaccination, 98.6% of infants receiving the RTS,S/AS02D vaccine had seropositive titers for anticircumsporozoite antibodies on enzyme-linked immunosorbent assay (ELISA). During the 6-month period after the third dose of vaccine, the efficacy of the RTS,S/AS02D vaccine against first infection with P. falciparum malaria was 65.2% (95% CI, 20.7 to 84.7; P=0.01). CONCLUSIONS: The use of the RTS,S/AS02D vaccine in infants had a promising safety profile, did not interfere with the immunologic responses to coadministered EPI antigens, and reduced the incidence of malaria infection. (ClinicalTrials.gov number, NCT00289185.) 2008 Massachusetts Medical Society
RCT Entities:
BACKGROUND: The RTS,S/AS malaria vaccine is being developed for delivery through the World Health Organization's Expanded Program on Immunization (EPI). We assessed the feasibility of integrating RTS,S/AS02D into a standard EPI schedule for infants. METHODS: In this phase 2B, single-center, double-blind, controlled trial involving 340 infants in Bagamoyo, Tanzania, we randomly assigned 340 infants to receive three doses of either the RTS,S/AS02D vaccine or the hepatitis B vaccine at 8, 12, and 16 weeks of age. All infants also received a vaccine containing diphtheria and tetanus toxoids, whole-cell pertussis vaccine, and conjugated Haemophilus influenzae type b vaccine (DTPw/Hib). The primary objectives were the occurrence of serious adverse events during a 9-month surveillance period and a demonstration of noninferiority of the responses to the EPI vaccines (DTPw/Hib and hepatitis B surface antigen) with coadministration of the RTS,S/AS02D vaccine, as compared with the hepatitis B vaccine. The detection of antibodies against Plasmodium falciparum circumsporozoite and efficacy against malaria infection were secondary objectives. RESULTS: At least one serious adverse event was reported in 31 of 170 infants who received the RTS,S/AS02D vaccine (18.2%; 95% confidence interval [CI], 12.7 to 24.9) and in 42 of 170 infants who received the hepatitis B vaccine (24.7%; 95% CI, 18.4 to 31.9). The results showed the noninferiority of the RTS,S/AS02D vaccine in terms of antibody responses to EPI antigens. One month after vaccination, 98.6% of infants receiving the RTS,S/AS02D vaccine had seropositive titers for anticircumsporozoite antibodies on enzyme-linked immunosorbent assay (ELISA). During the 6-month period after the third dose of vaccine, the efficacy of the RTS,S/AS02D vaccine against first infection with P. falciparum malaria was 65.2% (95% CI, 20.7 to 84.7; P=0.01). CONCLUSIONS: The use of the RTS,S/AS02D vaccine in infants had a promising safety profile, did not interfere with the immunologic responses to coadministered EPI antigens, and reduced the incidence of malaria infection. (ClinicalTrials.gov number, NCT00289185.) 2008 Massachusetts Medical Society
Authors: Obinna N Nnedu; Michael P O'Leary; Daniel Mutua; Beth Mutai; Mina Kalantari-Dehaghi; Al Jasinskas; Rie Nakajima-Sasaki; Grace John-Stewart; Phelgona Otieno; Xiaowu Liang; John Waitumbi; Francis Kimani; David Camerini; Philip L Felgner; Judd L Walson; Adam Vigil Journal: Proteomics Clin Appl Date: 2011-12 Impact factor: 3.494
Authors: D K Mathias; J L Plieskatt; J S Armistead; J M Bethony; K B Abdul-Majid; A McMillan; E Angov; M J Aryee; B Zhan; P Gillespie; B Keegan; A R Jariwala; W Rezende; M E Bottazzi; D G Scorpio; P J Hotez; R R Dinglasan Journal: Infect Immun Date: 2012-02-06 Impact factor: 3.441
Authors: Dmitri Kazmin; Helder I Nakaya; Eva K Lee; Matthew J Johnson; Robbert van der Most; Robert A van den Berg; W Ripley Ballou; Erik Jongert; Ulrike Wille-Reece; Christian Ockenhouse; Alan Aderem; Daniel E Zak; Jerald Sadoff; Jenny Hendriks; Jens Wrammert; Rafi Ahmed; Bali Pulendran Journal: Proc Natl Acad Sci U S A Date: 2017-02-13 Impact factor: 11.205
Authors: Peter D Crompton; Matthew A Kayala; Boubacar Traore; Kassoum Kayentao; Aissata Ongoiba; Greta E Weiss; Douglas M Molina; Chad R Burk; Michael Waisberg; Algis Jasinskas; Xiaolin Tan; Safiatou Doumbo; Didier Doumtabe; Younoussou Kone; David L Narum; Xiaowu Liang; Ogobara K Doumbo; Louis H Miller; Denise L Doolan; Pierre Baldi; Philip L Felgner; Susan K Pierce Journal: Proc Natl Acad Sci U S A Date: 2010-03-29 Impact factor: 11.205
Authors: Michelle M Adams; Payal Damani; Nicholas R Perl; Annie Won; Feng Hong; Philip O Livingston; Govind Ragupathi; David Y Gin Journal: J Am Chem Soc Date: 2010-02-17 Impact factor: 15.419